TIL
HEALTHCAREInstil Bio Inc
$8.01+0.18 (+2.30%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TIL Today?
No stock-specific AI insight has been generated for TIL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.67$42.79
$8.01
Fundamentals
Market Cap$54M
P/E Ratio—
EPS$-10.70
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume71K
Avg Volume (10D)—
Shares Outstanding6.8M
TIL News
20 articles- Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 27, 2026
- CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a TurnaroundMotley Fool·Feb 3, 2026
- Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.Motley Fool·Feb 3, 2026
- Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOncoYahoo Finance·Jan 6, 2026
- Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil BioYahoo Finance·Oct 21, 2025
- Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)Yahoo Finance·Sep 10, 2025
- Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the companyYahoo Finance·Aug 16, 2025
- Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 13, 2025
- ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in ChinaYahoo Finance·Jul 31, 2025
- Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsYahoo Finance·Jul 2, 2025
- Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowYahoo Finance·Jun 20, 2025
- Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetYahoo Finance·Jun 16, 2025
- Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramYahoo Finance·Jun 11, 2025
- Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceYahoo Finance·Jun 4, 2025
- Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerYahoo Finance·Jun 2, 2025
- Instil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceYahoo Finance·May 30, 2025
- Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·May 29, 2025
- Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeYahoo Finance·May 29, 2025
- Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoYahoo Finance·May 23, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$7.83
Day High$0.00
Day Low$0.00
52 Week High$42.79
52 Week Low$5.67
52-Week Range
$5.67$42.79
$8.01
Fundamentals
Market Cap$54M
P/E Ratio—
EPS$-10.70
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume71K
Avg Volume (10D)—
Shares Outstanding6.8M
About Instil Bio Inc
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. The company is headquartered in Dallas, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—